GLP-1 when your insurance changes: COBRA, marketplace, Medicare bridge, layoff

TLDR. Losing employer insurance, aging into Medicare, weighing COBRA, or switching plans all change your GLP-1 cost path. Six scenarios with concrete cost math: employer change with similar formulary (continue same drug, possibly switch pharmacy), employer change to restrictive formulary (PA + appeal or switch drug), COBRA bridge (high premium but same formulary), Medicare transition (Wegovy only via CVD indication, otherwise cash), Medicaid transition (15 states cover obesity GLP-1), and uninsured gap (NovoCare or LillyDirect direct programs at $149 to $549/mo). Plan the bridge before the change.

Insurance transitions are the single biggest cost cliff for patients on a GLP-1. Losing employer coverage at $25-$50 copay and discovering the cash-pay equivalent is $299-$549/month is the moment many patients quit. The transition is solvable; you just need the playbook before the cliff arrives.

Scenario 1: Employer layoff, COBRA window open

You've been laid off. COBRA continuation lets you keep the same employer plan for 18 months at full premium (typically $700-$1,500/month for the medical-and-pharmacy benefit). Your Wegovy or Zepbound copay stays the same.

The math: if COBRA premium is $900 and your alternative is cash-pay GLP-1 at $250/month, COBRA is paying $650/month for everything-else and saving you nothing on the GLP-1 specifically. Take COBRA only if you have other expensive ongoing care (specialist visits, other expensive meds) or you expect to be employed again within 60 days.

Cash-pay alternative: compounded semaglutide via Mochi ($178/mo flat), Henry Meds ($199 flat) or Medvi ($129 flat) is roughly $1,000 cheaper per year than brand Wegovy through NovoCare. The transition takes 1-3 weeks; do not let the COBRA window expire while you stall.

Scenario 2: Marketplace ACA plan

Most ACA marketplace plans exclude weight-loss medications. The narrow exception: silver-tier plans in 6-8 states that include obesity treatment as an essential health benefit (CA, NY, MA, OR, RI, VT, WA, plus DC).

If you're shopping the marketplace, check the formulary for Wegovy or Zepbound by exact brand name on the plan's drug-search tool before enrolling. If it's not there, your plan does not cover GLP-1 for weight loss. Diabetes-indicated Ozempic and Mounjaro coverage is more common on marketplace plans.

Scenario 3: Aging into Medicare at 65

If you were on employer insurance with Wegovy coverage and you turn 65, your Wegovy coverage changes based on your health status:

• You have established cardiovascular disease (post-MI, stroke or PAD): Medicare Part D will cover Wegovy under the cardiovascular indication. Find a Medicare-CV-aware program; see our Medicare-CV rankings.
• You have type 2 diabetes: Medicare Part D covers Ozempic and Mounjaro under the diabetes indication. See our Medicare-T2D rankings.
• You have neither: Medicare does not cover GLP-1 for weight loss alone. Cash-pay applies.

Plan the transition 60 days before your 65th birthday. Run the Medicare Part D enrollment so coverage starts the day Medicare kicks in. Don't skip a month.

Scenario 4: Job change with same insurer

If you're moving from Employer A to Employer B and both use Aetna (or BCBS, or UHC, etc.), your prior authorization typically transfers without re-running. The new employer's specific plan formulary may differ; verify Wegovy/Zepbound coverage at the new plan before you start.

If the new plan has different PA criteria (especially a six-month structured-lifestyle requirement you didn't need at the old plan), you may need to re-document. Bring your weight-loss history from the prior program to the new one.

Scenario 5: Job change with different insurer

If you're moving from Aetna to UHC (or any insurer change), assume the PA does not transfer. You'll need to re-run prior authorization at the new plan. Plan for a 4-8 week gap; during that gap, either bridge with cash-pay compounded or stockpile 4 weeks of medication before your last paycheck.

Programs that handle insurer-switching efficiently: PlushCare, Form Health, Knownwell. They've seen this transition many times.

Scenario 6: Marketplace tax-credit cliff

If your household income rose above the ACA premium-tax-credit eligibility threshold (currently 400% of FPL with the post-IRA extension, $60k for single, $124k for family of four), your marketplace premium may jump 3-5x at re-enrollment. This often makes ACA insurance unaffordable and pushes patients to cash-pay GLP-1.

The math: a $1,200/month marketplace premium with Wegovy coverage vs. no insurance + $178/mo compounded Mochi means you save $1,022/month by going uninsured. That's only sensible if you have no other major medical needs. Don't make this decision based on GLP-1 alone.

Bridging the gap during transitions

The cleanest bridge during any insurance transition is cash-pay compounded for 1-3 months. Specifically:

• Mochi at $178/mo flat: predictable cost, no lock-in, 48-hour onboarding
• Henry Meds at $199/mo flat: same model, different pharmacy
• Medvi at $129/mo flat: cheapest, newer

Stop the new program when your insurance coverage activates. Restart with brand Wegovy or Zepbound via prior authorization. Most patients don't notice the transition because the active molecule is the same.

For the broader cost-reduction landscape, see every cost-reduction pathway in 2026.

Frequently asked questions

What happens to my GLP-1 if I lose my job?

Three paths. COBRA continues your existing coverage for up to 18 months at full premium (typically $700 to $2,500 per month including the medication share). Marketplace coverage through healthcare.gov starts the first of the following month with subsidies based on income. Uninsured patients can route through NovoCare or LillyDirect direct programs at $149 to $549 per month. Plan the bridge before COBRA elections expire (60 days).

Does my GLP-1 transfer when I age into Medicare?

Mostly no for the obesity indication. Medicare Part D has a statutory exclusion for anti-obesity medications. Two exceptions: Wegovy for cardiovascular risk reduction in established CVD (covered after the 2024 SELECT label addition), and Ozempic or Mounjaro for type 2 diabetes under standard T2D criteria. Patients without CVD or T2D usually pay cash through NovoCare or LillyDirect on Medicare.

What if my employer switches plans and the new formulary excludes Wegovy?

File a formulary exception or PA with documentation that your current medication is medically necessary. About half of exception requests succeed when the prescriber documents that you have responded to Wegovy specifically and switching would harm continuity. If the exception fails, switch to the covered alternative (often Zepbound, sometimes Saxenda) under the new formulary.

Can I use a manufacturer copay card to bridge an insurance gap?

Only if you have active commercial insurance. The Wegovy and Zepbound savings programs require commercial coverage and exclude government insurance (Medicare, Medicaid, VA, TRICARE). During an insurance gap with no coverage, the cards do not apply; the cash-pay manufacturer direct programs (NovoCare, LillyDirect) are the bridge option.

How do I avoid running out of medication during an insurance change?

Build a 30-day buffer. Ask your prescriber for a 90-day supply right before the change (most plans cover 90-day mail-order) so you have inventory during the transition. File the new plan's PA the day coverage starts; do not wait. If a gap is unavoidable, route through NovoCare or LillyDirect cash for the gap month rather than stopping cold.